Trial Profile
An Observational Post-Authorization Safety Study (PASS) of MOVENTIG (Naloxegol) Drug Utilization in Selected European Populations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jul 2023
Price :
$35
*
At a glance
- Drugs Naloxegol (Primary)
- Indications Constipation
- Focus Adverse reactions
- Sponsors AstraZeneca; Kyowa Kirin Pharmaceutical Development
- 01 Apr 2021 Status has been changed to completed.
- 25 Sep 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 25 Sep 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.